How High Will Eli Lilly Stock Go By 2030?
The weight loss drugs market is heating up quickly and…
Sell
32
PLSE Quote, Financials, Valuation and Earnings
Last price:
$18.28
Seasonality move
:
19.33%
Day range:
$16.64 - $17.73
52-week range:
$6.60 - $25.00
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
10.13x
Volume:
127.2K
Avg. volume:
208.8K
1-year change:
140.47%
Market cap:
$1.2B
Revenue:
--
EPS (TTM):
-$0.81
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target DownsideNo price target exists because of limited analyst coverage.
-
Price Target UpsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Pulse Biosciences has -71.08% downside to fair value with a price target of -- per share.
PLSE vs. S&P 500
-
Over the past 5 trading days, Pulse Biosciences has overperformed the S&P 500 by 10.25% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Pulse Biosciences does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Pulse Biosciences has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Pulse Biosciences reported revenues of --.
Earnings Growth
-
Pulse Biosciences has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Pulse Biosciences reported earnings per share of -$0.18.
Enterprise value:
1B
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-28.66x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -$11.2M | -- | -- | -- | -- | |
| Operating Income | -$58.1M | -$43.6M | -$56.3M | -$12.5M | -$20.3M | |
| EBITDA | -$56.7M | -$42.4M | -$55.1M | -$12.2M | -$20M | |
| Diluted EPS | -$1.73 | -$0.88 | -$0.90 | -$0.21 | -$0.31 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $22.3M | $36.6M | $62.1M | $45.3M | $119.4M | |
| Total Assets | $41.3M | $54.2M | $77.9M | $59.2M | $132.5M | |
| Current Liabilities | $7.6M | $8.5M | $6M | $6.7M | $10.1M | |
| Total Liabilities | $18.4M | $18.6M | $80.1M | $14.8M | $17.6M | |
| Total Equity | $22.9M | $35.7M | -$2.2M | $44.4M | $114.9M | |
| Total Debt | -- | $436K | $65.9M | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$47M | -$33M | -$36.3M | -$6.8M | -$9.1M | |
| Cash From Investing | -$401K | -$121K | -$125K | -$43K | -$53K | |
| Cash From Financing | $79.9M | $16.4M | $110.1M | $804K | $48.2M | |
| Free Cash Flow | -$47.4M | -$33.2M | -$36.5M | -$6.8M | -$9.2M | |
PLSE
Sector
Market Cap
$1.2B
$34.2M
Price % of 52-Week High
69.16%
42.23%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.82%
1-Year Price Total Return
140.47%
-41.76%
Beta (5-Year)
1.874
0.737
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$16.58
200-day SMA
Sell
Level
$17.60
Bollinger Bands (100)
Sell
Level
16.26 - 20.22
Chaikin Money Flow
Sell
Level
-9.2M
20-day SMA
Buy
Level
$16.03
Relative Strength Index (RSI14)
Buy
Level
55.40
ADX Line
Buy
Level
15.97
Williams %R
Sell
Level
-19.9809
50-day SMA
Sell
Level
$17.81
MACD (12, 26)
Sell
Level
-0.06
25-day Aroon Oscillator
Buy
Level
36
On Balance Volume
Neutral
Level
6.4M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed-Field Ablation or nsPFA technology when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled.
Stock Forecast FAQ
In the current month, PLSE has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The PLSE average analyst price target in the past 3 months is --.
-
Where Will Pulse Biosciences Stock Be In 1 Year?
According to analysts, the consensus estimate is that Pulse Biosciences share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About Pulse Biosciences?
Analysts are divided on their view about Pulse Biosciences share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Pulse Biosciences is a Sell and believe this share price will rise from its current level to --.
-
What Is Pulse Biosciences's Price Target?
The price target for Pulse Biosciences over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is PLSE A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Pulse Biosciences is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of PLSE?
You can purchase shares of Pulse Biosciences via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Pulse Biosciences shares.
-
What Is The Pulse Biosciences Share Price Today?
Pulse Biosciences was last trading at $18.28 per share. This represents the most recent stock quote for Pulse Biosciences. Yesterday, Pulse Biosciences closed at $17.29 per share.
-
How To Buy Pulse Biosciences Stock Online?
In order to purchase Pulse Biosciences stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is TSMC the Best Semiconductor Stock to Buy Now?
The new administration has launched a slew of tariffs, paused…
Rocket Lab Vs Intuitive Machines Stock
The commercialization of outer space is now in full swing,…
Stock Ideas
Sell
48
Is AAPL Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 32x
Sell
43
Is MSFT Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 30x
Sell
40
Is NVDA Stock a Buy?
Market Cap: $2.4T
P/E Ratio: 33x
Alerts
Buy
58
AGX alert for Apr 22
Argan [AGX] is up 3.08% over the past day.
Sell
44
INOD alert for Apr 22
Innodata [INOD] is up 5.26% over the past day.
Sell
44
UHS alert for Apr 22
Universal Health Services [UHS] is up 2.73% over the past day.
